Espee Therapeutics Llp Profile
Key Indicators
- Obligation of Contribution ₹ 1.00 Cr
- Company Age 8 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.95 Cr
- Revenue Growth 80.34%
- Profit Growth 37.69%
- Ebitda 94.84%
- Total Assets 6.81%
About Espee Therapeutics Llp
Espee Therapeutics Llp (ETL) is 8 Year, 2 Months old Limited Liability Partnership 25 November 2016. Its registered office is in Ahmedabad, Gujarat, India.
The LLP status is Active, and it has filed its Accounts and Solvency Statement up to 31 Mar 2023 (FY 2022-2023). It's Total Obligation of Contribution is Rs 1.00 Cr as per MCA.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN/FCRN
AAH-8938
-
Incorporation Date
25 Nov 2016
-
Date of Accounts and Solvency Statement
31 Mar 2023
-
ROC Code
Roc-Ahmedabad
-
Company Classification
Limited Liability Partnership
Industry
Who are the key members and board of directors at Espee Therapeutics Llp?
Designated Partners (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Swapnil Shah
|
Designated Partner | 25-Nov-2016 | Current |
|
Anar Shah
|
Designated Partner | 25-Nov-2016 | Current |
Financial Performance of Espee Therapeutics Llp.
Espee Therapeutics Llp, for the financial year ended 2021, experienced significant growth in revenue, with a 80.34% increase. The company also saw a substantial improvement in profitability, with a 37.69% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Espee Therapeutics Llp?
Unlock access to Espee Therapeutics Llp's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Senores Pharmaceuticals LimitedSwapnil Shah is a mutual person
-
Remus Pharmaceuticals LimitedSwapnil Shah and Anar Shah are mutual person
-
Relius Lifesciences Private LimitedSwapnil Shah and Anar Shah are mutual person
-
Ratnatris Pharmaceuticals Private LimitedSwapnil Shah is a mutual person
-
Aelius Projects LlpSwapnil Shah and Anar Shah are mutual person
-
Renosen Pharmaceuticals Private Limited
Swapnil Shah and Anar Shah are mutual person
Charges (Loans)
₹9.95 Cr
₹0
Charges Breakdown by Lending Institutions
- Icici Bank Limited : 9.95 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Apr 2023 | Icici Bank Limited | ₹2.45 Cr | Open |
| 15 Jan 2021 | Icici Bank Limited | ₹7.50 Cr | Open |
How Many Employees Work at Espee Therapeutics Llp?
Espee Therapeutics Llp has a workforce of 15 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Espee Therapeutics Llp, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Espee Therapeutics Llp's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.